NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,665.22 mln
Float51.62 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-4.75
Highly reliable
1-Year Forecast
126
Exceptional upside
Relative Strength
37
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-30.22
Deeply negative
Business Description
Dianthus Therapeutics is a New York-based company founded in 2019 that focuses on treating serious autoimmune conditions through cutting-edge medical research. The company is advancing two promising drug candidates: one that precisely targets a key part of the immune system's complement pathway, and another that works in two ways at once to dial down harmful immune activity in certain white blood cells. Together, these treatments aim to offer new hope to patients whose immune systems attack their own bodies.
